Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Noelle V Frey,Saar Gill,Wei-Ting Hwang,Selina M. Luger,Mary Ellen Martin,Shannon R. McCurdy,Alison W. Loren,Keith W. Pratz,Alexander E. Perl,Julie Barber-Rotenberg,Amy Marshall,Marco Ruella,Simon F Lacey,Joseph Fraietta,Andrew Fesnak,Megan O'brien, Theresa Schanne,Jennifer L Brogdon,Boris Engels,Bruce L Levine

Blood（2021）

Cited 6|Views20
No score
Abstract
Background: Genetically modified T cells expressing an anti-CD19 murine chimeric antigen receptor (CAR) result in response rates of up to 90% in patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (ALL). Durable remissions are limited by relapses of both CD19+ disease, correlating with loss of persistence, and CD19- disease, due to target antigen loss. The use of humanized CAR T products with improved persistence and dual antigen targeting are strategies that may improve relapse free survival.
More
Translated text
Key words
hucart19,relapsed,patients,co-administered
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined